Medherant
Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018. Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use. The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system. As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
Mr Nigel Davis
CEO
MediSieve
MediSieve is a London-based medical device therapeutics company developing “magnetic blood filtration”, a revolutionary method of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. Practically any component can be specifically removed (cytokines, toxins, cells etc.), providing a platform technology that could be used to treat a huge range of blood-borne medical conditions, accessing several billion-dollar global markets. Our initial targets are sepsis, cytokine storms, leukaemia and malaria.
Dr George Frodsham
CEO
Mereo BioPharma Group plc
Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas. Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from AstraZeneca, for the treatment of diseases with considerable unmet medical need.
